Pargyline prevents MPTP-induced parkinsonism in primates - PubMed (original) (raw)
Pargyline prevents MPTP-induced parkinsonism in primates
J W Langston et al. Science. 1984.
Abstract
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin which produces permanent parkinsonism in human and nonhuman primates. Treatment of squirrel monkeys with pargyline, a monoamine oxidase (MAO) inhibitor, prevents both clinical and neuropathological evidence of the neurotoxic effects of MPTP. Pargyline also inhibits conversion of MPTP to 1-methyl-4-phenylpyridinium ion (MPP+), a metabolic step that occurs rapidly after administration of MPTP in animals not treated with pargyline. It is proposed that the conversion of MPTP to MPP+, possibly involving MAO, may be important for the neurotoxic effects of MPTP to take place, and MPTP itself may not be the neurotoxic agent.
Similar articles
- Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?
Irwin I, Langston JW. Irwin I, et al. Life Sci. 1985 Jan 21;36(3):207-12. doi: 10.1016/0024-3205(85)90060-8. Life Sci. 1985. PMID: 3871240 - Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.
Ransom BR, Kunis DM, Irwin I, Langston JW. Ransom BR, et al. Neurosci Lett. 1987 Apr 10;75(3):323-8. doi: 10.1016/0304-3940(87)90543-x. Neurosci Lett. 1987. PMID: 3495754 - The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P, Marsden CD. Jenner P, et al. J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review. - Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
Nakamura S, Vincent SR. Nakamura S, et al. Neurosci Lett. 1986 Apr 24;65(3):321-5. doi: 10.1016/0304-3940(86)90282-x. Neurosci Lett. 1986. PMID: 3487052 - Processing of MPTP by monoamine oxidases: implications for molecular toxicology.
Trevor AJ, Singer TP, Ramsay RR, Castagnoli N Jr. Trevor AJ, et al. J Neural Transm Suppl. 1987;23:73-89. doi: 10.1007/978-3-7091-8901-6_5. J Neural Transm Suppl. 1987. PMID: 3295117 Review.
Cited by
- The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Schultz W, Scarnati E, Sundström E, Tsutsumi T, Jonsson G. Schultz W, et al. Exp Brain Res. 1986;63(1):216-20. doi: 10.1007/BF00235666. Exp Brain Res. 1986. PMID: 3488228 - Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Close SP, Elliott PJ, Hayes AG, Marriott AS. Close SP, et al. Psychopharmacology (Berl). 1990;102(3):295-300. doi: 10.1007/BF02244093. Psychopharmacology (Berl). 1990. PMID: 1979176 - Needs and opportunities for innovation in psychopharmacology.
Stahl SM. Stahl SM. J R Soc Med. 1987 Jul;80(7):413-7. doi: 10.1177/014107688708000707. J R Soc Med. 1987. PMID: 3656311 Free PMC article. No abstract available. - The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice.
Vallucci M, Boutin JA, Janda E, Blandel F, Musgrove R, Di Monte D, Ferry G, Michel PP, Hirsch EC. Vallucci M, et al. J Neural Transm (Vienna). 2024 Jan;131(1):1-11. doi: 10.1007/s00702-023-02709-3. Epub 2023 Oct 18. J Neural Transm (Vienna). 2024. PMID: 37851107 - Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Masoud ST, Vecchio LM, Bergeron Y, Hossain MM, Nguyen LT, Bermejo MK, Kile B, Sotnikova TD, Siesser WB, Gainetdinov RR, Wightman RM, Caron MG, Richardson JR, Miller GW, Ramsey AJ, Cyr M, Salahpour A. Masoud ST, et al. Neurobiol Dis. 2015 Feb;74:66-75. doi: 10.1016/j.nbd.2014.10.016. Epub 2014 Oct 30. Neurobiol Dis. 2015. PMID: 25447236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources